BRIEF published on 04/21/2026 at 07:35, 13 days 10 hours ago Sensorion is preparing for its Annual General Meeting Shareholders General Assembly Preparatory Documents Remote Voting Sensory
BRIEF published on 04/21/2026 at 07:35, 13 days 10 hours ago Sensorion prépare son Assemblée Générale annuelle Actionnaires Assemblée Générale Documents Préparatoires Vote À Distance Sensorion
PRESS RELEASE published on 04/21/2026 at 07:30, 13 days 10 hours ago Terms of availability of the preparatory documents for the GM Sensorion provides Preliminary Documents for the Combined Shareholders' General Meeting of May 11, 2026. Shareholders urged to participate in a critical meeting addressing new therapies for hearing loss disorders Biotechnology Shareholders' Meeting Gene Therapy Sensorion Hearing Loss
PRESS RELEASE published on 04/21/2026 at 07:30, 13 days 10 hours ago Modalités de mise à disposition des documents préparatoires à l'AG Sensorion annonce la mise à disposition des documents préparatoires à l'Assemblée Générale mixte du 11 mai 2026. Les actionnaires peuvent voter à distance. Contact: contact@sensorion-pharma.com Actionnaires Documents Préparatoires Assemblée Générale Mixte Vote À Distance Sensorion
BRIEF published on 03/23/2026 at 07:35, 1 month 12 days ago Sensorion poursuit son développement en thérapie génique pour la surdité Thérapie Génique SENS-501 Surdité Congénitale Audiogene SENS-601
BRIEF published on 03/23/2026 at 07:35, 1 month 12 days ago Sensorion Updates on Audiogene Trial and Advances GJB2-GT Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 03/23/2026 at 07:35, 1 month 12 days ago Sensorion continues its development in gene therapy for deafness Gene Therapy Congenital Deafness Audiogene Sense-501 Sense-601
BRIEF published on 03/23/2026 at 07:35, 1 month 12 days ago Mises à jour de Sensorion sur l'essai Audiogene et les progrès du GJB2-GT Essais Cliniques Thérapie Génique Sensorion Perte Auditive SENS-601
PRESS RELEASE published on 03/23/2026 at 07:30, 1 month 12 days ago Informations privilégiées / Autres communiqués Sensorion publie les données à six mois de l’essai clinique de Phase 1/2 Audiogene pour SENS-501 et poursuit le développement clinique du GJB2-GT (SENS-601) vers une première administration chez l’homme Essai Clinique Thérapie Génique Sensorion Surdité GJB2-GT
BRIEF published on 03/18/2026 at 07:35, 1 month 17 days ago Sensorion Reports 2025 Results and Corporate Updates Financial Results Gene Therapy Sensorion Hearing Loss Sanofi Investment
Published on 05/04/2026 at 16:45, 1 hour 10 minutes ago Inventus Announces Engagement of Red Cloud Securities
Published on 05/04/2026 at 16:27, 1 hour 28 minutes ago Avenir Minerals to Acquire Fox River Resources in All-Cash Transaction for Approximately C$94.3 Million
Published on 05/04/2026 at 15:30, 2 hours 25 minutes ago Silver Spruce Resources Announces Resumption of Exploration at its Melchett Lake Au-Ag-Zn-Pb-Cu Volcanogenic Massive Sulphide Project, Nakina, Ontario
Published on 05/04/2026 at 15:00, 2 hours 55 minutes ago Shelfie Signs Definitive Agreement to Acquire Majority Interest in Israeli Based Aspect Information Systems Ltd.
Published on 05/04/2026 at 14:46, 3 hours 9 minutes ago Worksport (NASDAQ:WKSP) Invited to Present at D. Boral 2026 Global Conference
Published on 05/04/2026 at 17:40, 14 minutes ago BILENDI: Chiffre d’affaires du 1er trimestre 2026 : 20,8 M€, en croissance de +5,6%
Published on 05/04/2026 at 17:30, 25 minutes ago GEVELOT S.A.: Déclaration hebdomadaire de rachat d'actions 04 05 2026
Published on 05/04/2026 at 17:30, 25 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 05/04/2026 (French only)
Published on 05/04/2026 at 17:25, 29 minutes ago Conference call on the results for the 2nd quarter 2025/2026 (ending 31 March 2026) on 12 May 2026
Published on 05/04/2026 at 17:38, 17 minutes ago Reporting on share buyback transactions carried out between April 29 and April 30, 2026
